Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. FDA label
Anagrelide · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Anagrelide Hydrochloride Capsules 1 mg |
| 2 | ACTIVE_COMPARATOR | Agrylin® Capsules 1 mg |
| Name | Type | Description |
|---|---|---|
| Anagrelide Hydrochloride Capsules 1 mg | DRUG | 1mg, single dose fasting |
| Agrylin® Capsules 1 mg | DRUG | 1mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the ev...
Anagrelide is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is also known as anagrelide hydrochloride capsules 1 mg. The program is currently in Phase 1 clinical development, and the specific indication being studied is undisclosed.
Anagrelide targets PDE3A and PDE3B. It is classified as an inhibitor of these phosphodiesterase enzymes. This target profile places anagrelide in the small molecule modality, distinguishing it from biologic therapies that act through antibodies or recombinant proteins.
Anagrelide is developed by Viatris Inc., which trades under the ticker VTRS. The company is the sponsor of the clinical program evaluating anagrelide hydrochloride capsules 1 mg. No other developer or partnership is associated with this asset in the current development record.
Anagrelide is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for the undisclosed indication being studied. The program has completed two Phase 1 trials, with no active trials currently listed.
Two completed Phase 1 trials have evaluated anagrelide: NCT00648765, a fed-state study comparing anagrelide hydrochloride capsules 1 mg to Agrylin capsules 1 mg in 22 healthy volunteers, and NCT00648024, a fasting-state comparison in 47 healthy volunteers. Both were conducted in the United States.